Chihwan David Cha, Kyung Eun Kim, Jungbin Kim, Eunhae Um, Nayeon Choi, Jungsun Lee, Geumhee Gwak, Jae Il Kim, Min Sung Chung
{"title":"HER2低和HER2零状态早期乳腺癌患者的预后差异","authors":"Chihwan David Cha, Kyung Eun Kim, Jungbin Kim, Eunhae Um, Nayeon Choi, Jungsun Lee, Geumhee Gwak, Jae Il Kim, Min Sung Chung","doi":"10.1038/s41523-025-00737-8","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I-III). Survival analysis after propensity score matching was used. In total, 445 patients with HER2-low and 707 patients with HER2-zero status were included. The median follow-up was 92.7 months. Locoregional and distant recurrence-free survival were comparable between patients with HER2-low and HER2-zero status (p = 0.872, p = 0.746, respectively). HER2-low status did not affect overall survival. However, in subgroups with lymph node metastases, patients with HER2-low status showed better recurrence-free survival compared with that of patients with HER2-zero status (p = 0.033). In conclusion, survival outcomes were comparable between patients with HER2-low and HER2-zero breast cancer. More studies are needed to validate our findings and examine the biological mechanism underlying these prognostic differences.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"11 1","pages":"31"},"PeriodicalIF":7.6000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947260/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status.\",\"authors\":\"Chihwan David Cha, Kyung Eun Kim, Jungbin Kim, Eunhae Um, Nayeon Choi, Jungsun Lee, Geumhee Gwak, Jae Il Kim, Min Sung Chung\",\"doi\":\"10.1038/s41523-025-00737-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I-III). Survival analysis after propensity score matching was used. In total, 445 patients with HER2-low and 707 patients with HER2-zero status were included. The median follow-up was 92.7 months. Locoregional and distant recurrence-free survival were comparable between patients with HER2-low and HER2-zero status (p = 0.872, p = 0.746, respectively). HER2-low status did not affect overall survival. However, in subgroups with lymph node metastases, patients with HER2-low status showed better recurrence-free survival compared with that of patients with HER2-zero status (p = 0.033). In conclusion, survival outcomes were comparable between patients with HER2-low and HER2-zero breast cancer. More studies are needed to validate our findings and examine the biological mechanism underlying these prognostic differences.</p>\",\"PeriodicalId\":19247,\"journal\":{\"name\":\"NPJ Breast Cancer\",\"volume\":\"11 1\",\"pages\":\"31\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-03-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947260/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Breast Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41523-025-00737-8\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-025-00737-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status.
We aimed to investigate the differences in prognosis between patients with HER2-low and HER2-zero status. This retrospective cohort study conducted at multi-institution included 1627 patients diagnosed with HER2-low or HER2-zero breast cancer (stages I-III). Survival analysis after propensity score matching was used. In total, 445 patients with HER2-low and 707 patients with HER2-zero status were included. The median follow-up was 92.7 months. Locoregional and distant recurrence-free survival were comparable between patients with HER2-low and HER2-zero status (p = 0.872, p = 0.746, respectively). HER2-low status did not affect overall survival. However, in subgroups with lymph node metastases, patients with HER2-low status showed better recurrence-free survival compared with that of patients with HER2-zero status (p = 0.033). In conclusion, survival outcomes were comparable between patients with HER2-low and HER2-zero breast cancer. More studies are needed to validate our findings and examine the biological mechanism underlying these prognostic differences.
期刊介绍：
npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
